Development of endotoxin tolerance in humans in vivo

Critical Care Medicine

Volumn 37, Issue 4, 2009, Pages 1261-1267

  Draisma, Annelies ^a   Pickkers, Peter ^a   Bouw, Martijn P W J M ^a   Van Der Hoeven, Johannes G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cytokines; Endothelial cell activation; Endotoxemia; Endotoxin tolerance; Human; Leukocyte activation

Indexed keywords

ELASTASE; ESCHERICHIA COLI ENDOTOXIN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; HEART RATE; HEMODYNAMICS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; INFLAMMATION; INTENSIVE CARE UNIT; LABORATORY TEST; LEUKOCYTE ACTIVATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; VITAL SIGN;

CYTOKINES; ESCHERICHIA COLI; HUMANS; IMMUNE TOLERANCE; LIPOPOLYSACCHARIDES; MALE; YOUNG ADULT;

EID: 67650433962     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31819c3c67     Document Type: Article

References (52)

1. Bachofen M, Weibel ER: Structural alterations of lung parenchyma in the adult respiratory distress syndrome. Clin Chest Med 1982; 3:35-56
2. van Deventer SJ, Buller HR, ten Cate JW, et al: Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76:2520-2526
3. Greisman SE, Young EJ, Carozza FA, Jr: Mechanisms of endotoxin tolerance. V. Specificity of the early and late phases of pyrogenic tolerance. J Immunol 1969; 103: 1223-1236
4. Neter E: Endotoxins and the immune response. Curr Top Microbiol Immunol 1969; 47:82-124
5. Brooke MS: Conversion of immunological paralysis to immunity by endotoxin. Nature 1965; 206:635-636
6. Berry LJ, Smythe DS: Some metabolic aspects of tolerance to bacterial endotoxin. J Bacteriol 1965; 90:970-977
7. Milner KC: Patterns of tolerance to endotoxin. J Infect Dis 1973; 128(Suppl):237-245
8. Greisman SE, Hornick RB: Mechanisms of endotoxin tolerance with special reference to man. J Infect Dis 1973; 128(Suppl):265-276
9. Golub ES, Weigle WO: Studies on the induction of immunologic unresponsiveness. I. Effects of endotoxin and phytochemagglutinin. J Immunol 1967; 98:1241-1247
10. Colletti LM, Remick DG, Campbell DA, Jr: LPS pretreatment protects from hepatic ischemia/reperfusion. J Surg Res 1994; 57: 337-343
11. Dominguez FE, Siemers F, Flohe S, et al: Effects of endotoxin tolerance on liver function after hepatic ischemia/reperfusion injury in the rat. Crit Care Med 2002; 30: 165-170
12. Fernandez ED, Flohe S, Siemers F, et al: Endotoxin tolerance protects against local hepatic ischemia/reperfusion injury in the rat. J Endotoxin Res 2000; 6:321-328
13. Friedrich I, Spillner J, Lu EX, et al: Induction of endotoxin tolerance improves lung function after warm ischemia in dogs. Am J Physiol Lung Cell Mol Physiol 2003; 284: L224-L231
14. Godet C, Goujon JM, Petit I, et al: Endotoxin tolerance enhances interleukin-10 renal expression and decreases ischemia-reperfusion renal injury in rats. Shock 2006; 25:384-388
15. Heemann U, Szabo A, Hamar P, et al: Lipopolysaccharide pretreatment protects from renal ischemia/reperfusion injury: Possible connection to an interleukin-6-dependent pathway. Am J Pathol 2000; 156:287-293
16. Markart P, Schmidt R, Ruppert C, et al: Ischemic and endotoxin pre-conditioning reduce lung reperfusion injury-induced surfactant alterations. J Heart Lung Transplant 2005; 24:1680-1689
17. Yoshidome H, Kato A, Edwards MJ, et al: Interleukin-10 suppresses hepatic ischemia/ reperfusion injury in mice: Implications of a central role for nuclear factor kappaB. Hepatology 1999; 30:203-208
18. Shimauchi H, Ogawa T, Okuda K, et al: Au-toregulatory effect of interleukin-10 on proinflammatory cytokine production by Porphyromonas gingivalis lipopolysaccharide-tolerant human monocytes. Infect Immun 1999; 67:2153-2159
19. Frankenberger M, Pechumer H, Ziegler-Heitbrock HW: Interleukin-10 is upregulated in LPS tolerance. J Inflamm 1995; 45:56-63
20. Randow F, Syrbe U, Meisel C, et al: Mechanism of endotoxin desensitization: Involvement of interleukin 10 and transforming growth factor beta. J Exp Med 1995; 181: 1887-1892
21. Sly LM, Rauh MJ, Kalesnikoff J, et al: LPS-induced upregulation of SHIP is essential for endotoxin tolerance. Immunity 2004; 21: 227-239
22. Wolk K, Docke WD, von Baehr V, et al: Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood 2000; 96:218-223
23. Flohe S, Dominguez FE, Ackermann M, et al: Endotoxin tolerance in rats: Expression of TNF-alpha, IL-6, IL-10, VCAM-1 AND HSP 70 in lung and liver during endotoxin shock. Cytokine 1999; 11:796-804
24. Ackermann M, Reuter M, Flohe S, et al: Cytokine synthesis in the liver of endotoxintolerant and normal rats during hemorrhagic shock. J Endotoxin Res 2001; 7:105-112
25. Berg DJ, Kuhn R, Rajewsky K, et al: Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest 1995; 96: 2339-2347
26. Astiz ME, Rackow EC, Still JG, et al: Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: A prospective, double-blind, randomized, controlled trial. Crit Care Med 1995; 23:9-17
27. Dorresteijn MJ, van Eijk LT, Netea MG, et al: Iso-osmolar prehydration shifts the cytokine response towards a more anti-inflammatory balance in human endotoxemia. J Endotoxin Res 2005; 11:287-293
28. Draisma A, Dorresteijn M, Pickkers P, et al: The effect of systemic iNOS inhibition during human endotoxemia on the development of tolerance to different TLR-stimuli. Innate Immun 2008; 14:153-159
29. Pickkers P, Dorresteijn MJ, Bouw MP, et al: In vivo evidence for nitric oxide-mediated calcium-activated potassium-channel activation during human endotoxemia. Circulation 2006; 114:414-421
30. van Eijk LT, Dorresteijn MJ, Smits P, et al: Gender differences in the innate immune response and vascular reactivity following the administration of endotoxin to human volunteers. Crit Care Med 2007; 35: 1464-1469
31. Favorite GO, Morgan HR: Effects produced by the intravenous injection in man of a toxic antigenic material derived from eberhtella typhosa: Clinical, hematological, chemical and serological studies. J Clin Invest 1942; 21:589-599
32. Morgan HR: Tolerance to the toxic action of somatic antigens of enteric bacilli. J Immunol 1948; 59:129
33. Cavaillon JM, Dib-Conquy M: Bench-to-bedside review: Endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care 2006; 10:233
34. Zhang X, Morrison DC: Lipopolysaccharide structure-function relationship in activation versus reprogramming of mouse peritoneal macrophages. J Leukoc Biol 1993; 54: 444-450
35. Branger J, van den BB, Weijer S, et al: Inhibition of coagulation, fibrinolysis, and endo-thelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Blood 2003; 101: 4446-4448
36. Lemaire LC, de K, Giebelen IA, et al: Dobutamine does not influence inflammatory pathways during human endotoxemia. Crit Care Med 2006; 34:1365-1371
37. van der Poll T, van Deventer SJ, Pasterkamp G, et al: Tumor necrosis factor induces von Willebrand factor release in healthy humans. Thromb Haemost 1992; 67:623-626
38. Dahinden C, Galanos C, Fehr J: Granulocyte activation by endotoxin. I. Correlation between adherence and other granulocyte functions, and role of endotoxin structure on biologic activity. J Immunol1983; 130: 857-862
39. Smedly LA, Tonnesen MG, Sandhaus RA, et al: Neutrophil-mediated injury to endothelial cells. Enhancement by endotoxin and essential role of neutrophil elastase. J Clin Invest 1986; 77:1233-1243
40. Heemskerk S, Pickkers P, Bouw MP, et al: Upregulation of renal inducible nitric oxide synthase during human endotoxemia and sepsis is associated with proximal tubule injury. Clin J Am Soc Nephrol 2006; 1:853-862
41. He W, Fong Y, Marano MA, et al: Tolerance to endotoxin prevents mortality in infected thermal injury: Association with attenuated cytokine responses. J Infect Dis 1992; 165: 859-864
42. Barroso-Aranda J, Chavez-Chavez RH, Mathison JC, et al: Circulating neutrophil kinetics during tolerance in hemorrhagic shock using bacterial lipopolysaccharide. Am J Physiol 1994; 266:H415-H421
43. Brown JM, Grosso MA, Terada LS, et al: Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts. Proc Natl Acad Sci USA 1989; 86: 2516-2520
44. Eising GP, Mao L, Schmid-Schonbein GW, et al: Effects of induced tolerance to bacterial lipopolysaccharide on myocardial infarct size in rats. Cardiovasc Res 1996; 31:73-81
45. Wang YP, Sato C, Mizoguchi K, et al: Lipopolysaccharide triggers late preconditioning against myocardial infarction via inducible nitric oxide synthase. Cardiovasc Res 2002; 56:33-42
46. Yao Z, Auchampach JA, Pieper GM, et al: Cardioprotective effects of monophosphoryl lipid A, a novel endotoxin analogue, in the dog. Cardiovasc Res 1993; 27:832-838
47. Obermaier R, Drognitz O, Grub A, et al: Endotoxin preconditioning in pancreatic ischemia/reperfusion injury. Pancreas 2003; 27: e51-e56
48. Ahmed SH, He YY, Nassief A, et al: Effects of lipopolysaccharide priming on acute ischemic brain injury. Stroke 2000; 31:193-199
49. Bordet R, Deplanque D, Maboudou P, et al: Increase in endogenous brain superoxide dis-mutase as a potential mechanism of lipopo-lysaccharide-induced brain ischemic tolerance. J Cereb Blood Flow Metab 2000; 20: 1190-1196
50. Dawson DA, Furuya K, Gotoh J, et al: Cere-brovascular hemodynamics and ischemic tolerance: Lipopolysaccharide-induced resistance to focal cerebral ischemia is not due to changes in severity of the initial ischemic insult, but is associated with preservation of microvascular perfusion. J Cereb Blood Flow Metab 1999; 19:616-623
51. Rosenzweig HL, Lessov NS, Henshall DC, et al: Endotoxin preconditioning prevents cellular inflammatory response during ischemic neuroprotection in mice. Stroke 2004; 35: 2576-2581
52. Tasaki K, Ruetzler CA, Ohtsuki T, et al: Lipopolysaccharide pre-treatment induces resistance against subsequent focal cerebral ischemic damage in spontaneously hypertensive rats. Brain Res 1997; 748:267-270